---
title: Martine Rothblatt Sold About $1.5M in United Therapeutics Stock During December 2025 While Exercising Options
type: news
slug: martine-rothblatt-sold-united-therapeutics-stock-december-2025
canonical_url: https://13finsight.com/news/martine-rothblatt-sold-united-therapeutics-stock-december-2025
published_at: 2026-03-09T18:23:47.428Z
updated_at: 2026-03-23T07:03:49.764Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 220
locale: en
source: 13F Insight
---

# Martine Rothblatt Sold About $1.5M in United Therapeutics Stock During December 2025 While Exercising Options

> United Therapeutics CEO Martine Rothblatt exercised options and sold UTHR shares worth ~$1.5M across December 17-19, 2025 at prices around $505-$511 per share.

What HappenedMartine Rothblatt, CEO of United Therapeutics Corp (UTHR), executed a series of option exercises and stock sales during December 17-19, 2025. The pattern was consistent: exercise options at $120.26 per share, then sell the resulting shares at market prices between $505 and $511.Transaction DetailsDateActionSharesPrice2025-12-17M (Exercise)4,000—2025-12-18M (Exercise)4,000$120.262025-12-18S (Sale)2,000$507.242025-12-18S (Sale)500$509.422025-12-18S (Sale)1,500$510.862025-12-19M (Exercise)2,000$120.262025-12-19S (Sale)500$505.452025-12-19S (Sale)1,500$507.61Total sales: approximately 6,000 shares at prices averaging ~$508, for roughly $3.0M in proceeds. After transactions, Rothblatt owned just 130 shares directly.Why It MattersThe exercise-and-sell pattern is common for executives whose compensation is heavily options-based. Rothblatt exercised at $120.26 (the original grant price) and sold at ~$508, locking in a ~$388 per-share profit — a 322% gain on the options. With only 130 shares remaining after the sales, Rothblatt has effectively monetized her direct equity stake.Note that Rothblatt’s career Form 4 data shows $1.05 billion in total reported sell value across her tenure — reflecting systematic monetization of option grants over many years.ContextUnited Therapeutics is a biotechnology company focused on organ manufacturing and pulmonary arterial hypertension treatments. UTHR shares have performed well, trading above $500, which explains why Rothblatt’s older $120 options are deeply in-the-money.What to WatchWhether Rothblatt exercises additional option tranches in upcoming quartersUTHR’s pipeline updates on xenotransplantation and lung manufacturingThe very low remaining direct ownership (130 shares) — though Rothblatt may hold shares through other entities

---

Source: 13F Insight — https://13finsight.com/news/martine-rothblatt-sold-united-therapeutics-stock-december-2025
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-23T07:03:49.764Z